Categories: CenterDrugInvestmentLEDTechnology
Leveraging new understandings in the molecular biology of inflammation to create novel medicines that treat patients with severe inflammatory diseases.
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.03.2020 | Series A | $50M | - |
Mentions in press and media 7
| Date | Title | Description |
| 28.09.2020 | Quench Bio is named one of Fierce Biotech's "Fierce 15" Biotech Companies of 2020 | |
| 27.01.2020 | Quench Bio Raises $50M in Series A Financing | Quench Bio, a Cambridge, Mass.-based company leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, completed a $50m Series A financing.
The round was led by RA Capital Ma... |
| 27.01.2020 | Quench Bio Closes $50M Series A Financing | Quench Bio, a company leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, today announced the completion of a $50 million Series A financing led by RA Capital Managemen... |
| 27.01.2020 | Quench Bio, a biotech startup co-founded by Arix, emerges from stealth with $50M Series A funding | Quench Bio, a biotech startup co-founded by Arix Bioscience and Atlas Venture, has emerged from stealth mode with a total of $50 million in Series A funding. Quench is leveraging new insights into gasdermin biology and innate immunity to de... |
| 27.01.2020 | Quench Bio Closes $50M Series A Financing |
CAMBRIDGE, MA, Quench Bio announced the completion of a $50 million Series A financing led by RA Capital Management.
>> Click here for more funding data on Quench Bio
>> To export Quench Bio funding data to PDF and Excel, cl... |
| 27.01.2020 | Quench Bio emerges with $50M to treat severe inflammatory diseases | Most treatments for inflammatory diseases have single targets, such as an inflammation-promoting cytokine or a protein complex called an inflammasome. Quench Bio is taking aim at a family of proteins involved in inflammatory cell death—and ... |
| 27.01.2020 | Quench Bio emerges with $50M to treat severe inflammatory diseases | Most treatments for inflammatory diseases have single targets, such as an inflammation-promoting cytokine or a protein complex called an inflammasome. Quench Bio is taking aim at a family of proteins involved in inflammatory cell death—and ... |
Reviews 0